by Webdesign Squad | Jul 23, 2021 | Uncategorized
AFFLUENT MEDICAL launches its IPO on the regulated Euronext Paris market • Capital increase of approximately €33.0 million, which may be increased to approximately €43.6 million in the event of the full exercise of the extension and over-allotment clause •...
by Webdesign Squad | Jul 23, 2021 | Uncategorized
Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve to restore blood flow and reduce the risk of cardiac insufficiency. • Preclinical in vivo results published in The Annals of...
by Webdesign Squad | Jul 23, 2021 | Uncategorized
AFFLUENT MEDICAL announces the approval of its Registration Document by the French Financial Markets Authority (Autorité des marchés financiers – AMF) as part of its proposed IPO on the Euronext Paris regulated market Affluent Medical, a French medtech specialising in...
by Webdesign Squad | Mar 5, 2021 | Uncategorized
The Private Placement Financing was taken out for gross proceeds of €10.3 million, €8 million via convertible bonds (of which €4 million were received in December 2019). Affluent Medical has been granted two “PGE” (government-backed) loans for a total of €2.2 million...
by Webdesign Squad | Mar 5, 2021 | Uncategorized
Epygon is the first transcatheter mitral valve designed to restore the physiological blood flow vortex and treat left ventricle disease, in particular in so-called “functional” patients. No mitral valve prosthesis currently on the market or in development was designed...
Recent Comments